• Something wrong with this record ?

Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters

A. Sorf, E. Novotna, J. Hofman, A. Morell, F. Staud, V. Wsol, M. Ceckova,

. 2019 ; 163 (-) : 290-298. [pub] 20190228

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20006552

Daunorubicin (DAUN) has served as an anticancer drug in chemotherapy regimens for decades and is still irreplaceable in treatment of acute leukemias. The therapeutic outcome of DAUN-based therapy is compromised by its cardiotoxicity and emergence of drug resistance. This phenomenon is often caused by pharmacokinetic mechanisms such as efflux of DAUN from cancer cells through ATP-binding cassette (ABC) transporters and its conversion to less cytostatic but more cardiotoxic daunorubicinol (DAUN-OL) by carbonyl reducing enzymes (CREs). Here we aimed to investigate, whether two cyclin-dependent kinase inhibitors, AZD5438 and R547, can interact with these pharmacokinetic mechanisms and reverse DAUN resistance. Using accumulation assays, we revealed AZD5438 as potent inhibitor of ABCC1 showing also weaker inhibitory effect to ABCB1 and ABCG2. Combination index analysis, however, shown that inhibition of ABCC1 does not significantly contribute to synergism between AZD5438 and DAUN in MDCKII-ABCC1 cells, suggesting predominant role of other mechanism. Using pure recombinant enzymes, we found both tested drugs to inhibit CREs with aldo-keto reductase 1C3 (AKR1C3). This interaction was further confirmed in transfected HCT-116 cells. Moreover, these cells were sensitized to DAUN by both compounds as Chou-Talalay combination index analysis showed synergism in AKR1C3 transfected HCT-116, but not in empty vector transfected control cell line. In conclusion, we propose AZD5438 and R547 as modulators of DAUN resistance that can prevent AKR1C3-mediated DAUN biotransformation to DAUN-OL. This interaction could be beneficially exploited to prevent failure of DAUN-based therapy as well as the undesirable cardiotoxic effect of DAUN-OL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006552
003      
CZ-PrNML
005      
20200527081802.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2019.02.035 $2 doi
035    __
$a (PubMed)30826329
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Sorf, Ales $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
245    10
$a Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters / $c A. Sorf, E. Novotna, J. Hofman, A. Morell, F. Staud, V. Wsol, M. Ceckova,
520    9_
$a Daunorubicin (DAUN) has served as an anticancer drug in chemotherapy regimens for decades and is still irreplaceable in treatment of acute leukemias. The therapeutic outcome of DAUN-based therapy is compromised by its cardiotoxicity and emergence of drug resistance. This phenomenon is often caused by pharmacokinetic mechanisms such as efflux of DAUN from cancer cells through ATP-binding cassette (ABC) transporters and its conversion to less cytostatic but more cardiotoxic daunorubicinol (DAUN-OL) by carbonyl reducing enzymes (CREs). Here we aimed to investigate, whether two cyclin-dependent kinase inhibitors, AZD5438 and R547, can interact with these pharmacokinetic mechanisms and reverse DAUN resistance. Using accumulation assays, we revealed AZD5438 as potent inhibitor of ABCC1 showing also weaker inhibitory effect to ABCB1 and ABCG2. Combination index analysis, however, shown that inhibition of ABCC1 does not significantly contribute to synergism between AZD5438 and DAUN in MDCKII-ABCC1 cells, suggesting predominant role of other mechanism. Using pure recombinant enzymes, we found both tested drugs to inhibit CREs with aldo-keto reductase 1C3 (AKR1C3). This interaction was further confirmed in transfected HCT-116 cells. Moreover, these cells were sensitized to DAUN by both compounds as Chou-Talalay combination index analysis showed synergism in AKR1C3 transfected HCT-116, but not in empty vector transfected control cell line. In conclusion, we propose AZD5438 and R547 as modulators of DAUN resistance that can prevent AKR1C3-mediated DAUN biotransformation to DAUN-OL. This interaction could be beneficially exploited to prevent failure of DAUN-based therapy as well as the undesirable cardiotoxic effect of DAUN-OL.
650    _2
$a ABC transportér z rodiny G, člen 2 $x metabolismus $7 D000070997
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x aplikace a dávkování $x terapeutické užití $7 D000970
650    _2
$a vazebná místa $7 D001665
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $7 D049109
650    _2
$a klonování DNA $7 D003001
650    _2
$a daunomycin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D003630
650    _2
$a psi $7 D004285
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a regulace genové exprese enzymů $x účinky léků $7 D015971
650    _2
$a nemoci srdce $x chemicky indukované $7 D006331
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $x aplikace a dávkování $x farmakologie $7 D007093
650    _2
$a proteiny spojené s mnohočetnou rezistencí k lékům $x metabolismus $7 D027425
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a vazba proteinů $7 D011485
650    _2
$a pyrimidiny $x aplikace a dávkování $x farmakologie $7 D011743
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Novotna, Eva $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Hofman, Jakub $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Morell, Anselm $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Staud, Frantisek $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Wsol, Vladimir $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Ceckova, Martina $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. Electronic address: martina.ceckova@faf.cuni.cz.
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 163, č. - (2019), s. 290-298
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30826329 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200527081758 $b ABA008
999    __
$a ok $b bmc $g 1525410 $s 1096608
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 163 $c - $d 290-298 $e 20190228 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options